Peptide– tag –
-
Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth
BioProcess International South Korea Overview On September 10, 2026, Samsung Biologics announced a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. This substantial contract will further accelerat... -
Oral GLP-1 Receptor Agonists Foundayo (Orforglipron) and Wegovy Pill (Oral Semaglutide) Demonstrate Average Weight Loss of 12.4% and 16.6% Respectively by 2026
PrivateDoc® Unknown Overview By 2026, two oral GLP-1 receptor agonists, Foundayo (orforglipron) and Wegovy pill (oral semaglutide), are approved for weight management in the UK. Foundayo, a small-molecule non-peptide, can be taken with o... -
Eli Lilly’s Foundayo® (Orforglipron) Receives FDA Approval as First Oral Non-Peptide GLP-1 Receptor Agonist, Demonstrates Significant Weight Loss and Cardiometabolic Improvement
Obesity Medicine Review Unknown Overview Eli Lilly's Orforglipron, branded as Foundayo®, has received FDA approval as the latest oral GLP-1 receptor agonist. Distinguishing itself from oral semaglutide (Wegovy®) as a small-molecule, non-... -
Gan & Lee Pharmaceuticals Initiates Phase I Trial for Once-Weekly Oral GLP-1 Peptide GZC8072 in China, Targeting Obesity and Type 2 Diabetes
AllSci China Overview Gan & Lee Pharmaceuticals Co., Ltd. has commenced its Phase I clinical trial for GZC8072, a novel once-weekly oral GLP-1 receptor peptide agonist, targeting type 2 diabetes and weight management in overweight or... -
Eli Lilly’s Oral GLP-1 Agonist Orforglipron Shows Promising Weight Loss and Safety in Phase 2 Trials, Rivaling Injectables
Endocrinology Today USA Overview Eli Lilly's investigational oral GLP-1 receptor agonist, Orforglipron, demonstrated weight loss comparable to some injectable GLP-1s in Phase 2 trials for obesity and type 2 diabetes. As a non-peptide sma... -
Catalent Secures $4.1B Refinancing, Fuels Major Expansion in Biologics and Oral Drug Manufacturing to Meet GLP-1 Demand
Pharmaceutical Technology USA Overview Catalent successfully completed a $4.1 billion debt refinancing, earmarking substantial capital for expanding its biologics and oral drug manufacturing capacity. These strategic investments, includi... -
Antibody-Drug Conjugates Prepared with Peptide Asparaginyl Ligase Enhance Uniformity and Antitumor Activity, Promising Pharmaceutical Applications
Molecular Cancer Therapeutics (AACR Journals) USA Overview Novel antibody-drug conjugates (ADCs) prepared using peptide asparaginyl ligase (PAL) demonstrated potent antitumor activity in both in vitro and in vivo models. This innovative ... -
Samsung Biologics to Acquire PolyPeptide Group for $1.8B, Expanding CDMO Capabilities into Peptide Therapeutics with $2.2B Capital Raise
Endpoints News South Korea Overview Samsung Biologics announced a capital raise of nearly $2.2 billion to fund its long-term growth strategy, including the acquisition of PolyPeptide Group for $1.8 billion. This acquisition will signific... -
Oral Absorption of Therapeutic Peptides Remains Below 1%, MDPI Review Identifies Enzymatic Degradation, pH, Microbiota as Key Barriers
MDPI Unknown Overview A new MDPI review provides a comprehensive analysis of the complex physiological determinants influencing the oral absorption of therapeutic peptides. It confirms that the bioavailability of oral peptides typically ... -
Viking Therapeutics Initiates Phase 2 VENTURE-Oral Trial for Oral Dual GLP-1/GIP Agonist VK2735 in Obesity
Superpower USA Overview Viking Therapeutics has commenced its Phase 2 VENTURE-Oral trial in early 2025 for VK2735, an oral dual GLP-1/GIP receptor agonist targeting obesity. This move highlights the intense competition in the metabolic d...
